In This Issue
Journal: Cancer Discovery (2022)

In This Issue| October 05 2022 In This Issue Author & Article Information Online ISSN: 2159-8290 Print ISSN: 2159-8274 ©2022 American Association for Cancer Research2022American Association for Cancer Research Cancer Discov (2022) 12 (10): 2221–2223. https://doi.org/10.1158/2159-8290.CD-12-10-ITI Related Content A commentary has been published: Modulation of BCL-2 in Both T Cells and Tumor Cells to Enhance Chimeric Antigen Receptor T-cell Immunotherapy against Cancer A commentary has been published: Geospatial Immune Heterogeneity Reflects the Diverse Tumor–Immune Interactions in Intrahepatic Cholangiocarcinoma A commentary has been published: A Cancer Cell–Intrinsic GOT2–PPARδ Axis Suppresses Antitumor Immunity View more A commentary has been published: A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma A commentary has been published: Escherichia coli–Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer A commentary has been published: Single-Cell Sequencing Reveals Trajectory of Tumor-Infiltrating Lymphocyte States in Pancreatic Cancer A commentary has been published: The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation A commentary has been published: Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation A commentary has been published: Reprogrammed Schwann Cells Organize into Dynamic Tracks that Promote Pancreatic Cancer Invasion View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record October 5 2022 Citation In This Issue. Cancer Discov 1 October 2022; 12 (10): 2221–2223. https://doi.org/10.1158/2159-8290.CD-12-10-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Accurate biomarkers of immune checkpoint blocker (ICB) response remain a need in metastatic muscle-invasive bladder cancer (MIBC); therefore, Goubet and colleagues sought to determine biomarkers to guide use of neoadjuvant ICBs in localized MIBC. Follicular helper CD4+ T cells (TFH) and IgG against urothelium-invasive Escherichia coli were found to direct clinical response such as progression-free survival after pembrolizumab treatment. CXCL13 produced by tumor-localized blood central memory TFH cells was found in the plasma of patients who responded, and IgG3+ CD38+ TFH cells present in bladder tissues were correlated with clinical benefit, suggesting a potential link between tumor infection and the success of ICBs. See article, p. 2280. Distant metastases arise in about half of patients after surgical removal of localized clear-cell renal cell carcinoma (ccRCC) tumors. There remains a need to accurately identify which patients are likely to relapse and to develop... You do not currently have access to this content.